Markets:

Overview

News

Currencies

International

Treasuries

Krystal Biotech, Inc. - Common Stock (NQ:KRYS)

283.70 -48.59 (-14.62%)

Delayed Quote Updated: 12:39 PM EST, Nov 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Krystal Biotech, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Krystal Biotech (KRYS) Q3 2026 Earnings Call Transcript ↗

Today 11:58 EST

VYJUVEK revenue surged 30% YoY to $127.3 million amid $400 million buyback authorization.

Via The Motley Fool

Topics Earnings

Krystal Biotech Q3 Earnings Call Highlights ↗

Today 11:14 EST

Krystal Biotech (NASDAQ:KRYS) reported third-quarter 2026 revenue growth driven by continued adoption of its VYJUVEK treatment in the United States and international markets, while also outlining...

Via MarketBeat

Topics Earnings

Here’s How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years ↗

September 10, 2026

Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 32.48% on an annualized basis producing an average annual return of 43.76%. Currently, Krystal Biotech has a market...

Via Benzinga

Here’s How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years ↗

August 25, 2026

Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 32.97% on an annualized basis producing an average annual return of 44.08%. Currently, Krystal Biotech has a market...

Via Benzinga

Krystal Biotech (NASDAQ:KRYS) Clears Minervini Trend Template and High Growth Momentum Screen ↗

August 22, 2026

Via Chartmill

Krystal Biotech (NASDAQ:KRYS) Slips After Q2 Revenue Miss Despite EPS Beat ↗

August 03, 2026

Via Chartmill

Krystal Biotech (NASDAQ:KRYS) Shows High-Growth Momentum With Perfect Minervini Trend Template Setup ↗

July 16, 2026

Via Chartmill

Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More ↗

August 14, 2026

The drugmaker should significantly mitigate its most important risk as it develops new products.

Via The Motley Fool

Krystal Biotech (KRYS) Q2 2026 Earnings Call Transcript ↗

August 10, 2026

VYJUVEK revenue surged 24% as the company eyes a multiproduct pipeline transition.

Via The Motley Fool

Topics Earnings

If You Invested $1000 In Krystal Biotech Stock 5 Years Ago, You Would Have This Much Today ↗

August 10, 2026

Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 31.0% on an annualized basis producing an average annual return of 42.63%. Currently, Krystal Biotech has a market...

Via Benzinga

Krystal Biotech (NASDAQ:KRYS) Combines Perfect Trend Template with High-Growth Momentum ↗

May 09, 2026

Via Chartmill

Krystal Biotech (NASDAQ:KRYS) Surges After Q1 Beat as VYJUVEK Revenue Hits $116.4M ↗

May 04, 2026

Via Chartmill

Krystal Biotech Q2 Earnings Call Highlights ↗

August 03, 2026

Krystal Biotech (NASDAQ:KRYS) reported second-quarter 2026 net revenue of $119.2 million from global sales of VYJUVEK, up 24% from $96 million in the prior-year period, as the company expanded...

Via MarketBeat

Topics Earnings

These 3 Healthcare Stocks Have Crushed the Market This Year. Here's Why There's More Upside Ahead ↗

July 24, 2026

They are riding strong tailwinds that could lift them higher.

Via The Motley Fool

Topics Economy

Why Tutor Perini Stock Trounced the Market on Tuesday ↗

July 21, 2026

It's about to join a notable small-cap stock index.

Via The Motley Fool

Topics Stocks

3 Soaring Stocks That May Have More Upside Ahead ↗

July 07, 2026

The sky is the limit for these companies.

Via The Motley Fool

3 Biotech Firms With Major Potential Catalysts in the Coming Months ↗

June 21, 2026

The pharmaceutical industry is known for big risks and big rewards among investors; those willing to take on the risk may want to watch these firms.

Via MarketBeat

Topics Intellectual Property

These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside Ahead ↗

June 18, 2026

They haven't peaked yet.

Via The Motley Fool

Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More ↗

May 30, 2026

Vericel develops cell therapies for cartilage repair and burn care, serving hospitals and clinics across the United States.

Via The Motley Fool

Topics Regulatory Compliance

Why This Tech Fund Made a $5.8 Million Bet on an AI Chip Stock Up Nearly 200% Post-IPO ↗

May 14, 2026

Ambiq Micro designs ultra-low-power chips for wearables, IoT, and edge AI, targeting energy efficiency in connected devices.

Via The Motley Fool

Topics Artificial Intelligence Initial Public Offering Regulatory Compliance

This AI Semiconductor Stock Beat the S&P 500 by 9 Points. A Fund Just Exited Completely ↗

May 14, 2026

Ambarella delivers advanced semiconductor solutions for video, AI, and computer vision across automotive, security, and robotics markets.

Via The Motley Fool

Topics Artificial Intelligence Regulatory Compliance Stocks

Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position ↗

May 10, 2026

This clinical-stage biotech develops oral therapeutics for chronic diseases, targeting large global markets with unmet medical needs.

Via The Motley Fool

Topics Regulatory Compliance

Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug ↗

May 10, 2026

Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition technology.

Via The Motley Fool

Krystal (KRYS) Q1 2026 Earnings Transcript ↗

May 04, 2026

Krystal (KRYS) Q1 2026 Earnings Transcript

Via The Motley Fool

Krystal (KRYS) Q1 2025 Earnings Transcript ↗

May 04, 2026

Krystal (KRYS) Q1 2025 Earnings Transcript

Via The Motley Fool

Is Paymentus Stock a Buy After Palisades Investment Partners Increased Its Stake By $6 Million? ↗

May 01, 2026

Paymentus delivers cloud-based bill payment technology to major enterprises across regulated and service-intensive industries.

Via The Motley Fool

Topics Regulatory Compliance

Is Amprius Technologies Stock a Buy After Palisades Investment Partners Initiated a Position Worth $4.8 Million? ↗

May 01, 2026

Amprius Technologies manufactures silicon nanowire lithium-ion batteries for aerospace, defense, and electric mobility markets.

Via The Motley Fool

Topics Electric Vehicles Regulatory Compliance

Palisades Investment Partners Initiated a Position in SkyWater Technology Stock. What Does This Mean for Investors? ↗

May 01, 2026

SkyWater Technology delivers custom semiconductor solutions for sectors including aerospace, automotive, and industrial IoT.

Via The Motley Fool

Topics Regulatory Compliance

3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist ↗

April 16, 2026

These companies boast significant upside potential.

Via The Motley Fool

Is Vertex Pharmaceuticals' Empire in Trouble? ↗

April 16, 2026

It might not be too late to invest in this company.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.